Published on : Aug 28, 2017
Albany, New York, August 28, 2017: Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer-related deaths in men in the United States. Cancer cells can spread from the prostate to other parts of the body. This spread is called metastasis. Continuous advances have provided a new understanding of the diagnosis, staging, and treatment of metastatic and advanced prostate cancer. A new study, titled “Metastatic Prostate Cancer-Pipeline Insight, 2017” has been freshly broadcasted to the wide repository of Market Research Hub (MRH), which provides comprehensive insights about the pipeline drugs across Metastatic Prostate Cancer. Also, this report provides information on the therapeutic development for Metastatic Prostate Cancer, dealing with all the pipeline drugs and relative analysis at various stages covering all clinical, pre-clinical as well as discovery products.
Currently, men facing metastatic prostate cancer have several treatment options. Systemic therapies for metastatic prostate cancer include hormone therapy, chemotherapy, immunotherapy/vaccine treatment and Radium-223. In addition, there are many drugs in the pipeline such as Tc-99m (Progenics), radium-223 dichloride (Xofigo, Bayer) and ODM-201 (Orion and Bayer), which are in their phase 3 studies and are probable to enter the market in the coming years. The goal of these therapies is to halt cancer growth, control pain, alleviate symptoms and prolong survival.
Further, the pipeline study contains details on dormant products and discontinued products. Besides, the report tracks the major market events including product launches, technological developments, mergers & acquisitions, and the innovative business strategies opted by key market players. Therapeutic assessment of all the active products by route of administration (RoA) and molecule type is also analyzed in this report. This subsequent section on pipeline products features product description, mechanism of action, chemical details and research & development progress.
Medical oncologists with expertise in prostate cancer manage the treatment of men with metastatic disease. It has been analyzed that a drug named ‘Zytiga’ is a gold standard for the treatment of prostate cancer and is witnessing rapid rise in sales year on year. However, rapid development & adoption of immunotherapy drugs are expected to result in fast growth of this drug class. According to the findings, approval of new technologies, improving healthcare infrastructure and growing investments by market players for the development of immunotherapies and targeted therapies, which is resulting in a strong pipeline, are some of the factors expected to trigger growth of the therapeutics market for metastatic prostate cancer.
For the clear understanding of the market, the report provides data and information largely sourced from proprietary databases, primary and secondary research and in-house analysis by the team of industry experts. Some of the secondary sources utilized in the study include trade journals, news websites, search engines, magazines, industry portals and others.
Request a Sample with TOC in a PDF format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1265406
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org